Skip to main content
TLSA
NASDAQ Life Sciences

Tiziana Reports Consistent Brain Inflammation Reduction in Third MSA Patient Treated with Intranasal Foralumab

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$0.953
Mkt Cap
$124.46M
52W Low
$0.866
52W High
$2.6
52W Position info
10.0% above low
Off High info
63% below high
Rel. Volume info
0.1× avg
Market data snapshot near publication time

TLSA is trading near its 52-week low of $0.866 (10.0% above the low) on light trading volume (0.1× avg).

Summary

Tiziana announced PET imaging results from the third MSA patient in its Phase 2 trial of intranasal foralumab, showing up to a 34% reduction in brain inflammation—consistent with the first two patients. The reproducible signal supports the drug's potential in a disease with no approved therapies.


Key Events · Product Development and Regulatory · TLSA

  • Third MSA Patient Shows Consistent Inflammation Reduction

    Quantitative PET imaging revealed up to a 34% reduction in SUV and a 26% reduction in SUVR in the basal ganglia and cerebellar white matter, closely matching the ~35% SUV and 24% SUVR reductions seen in the first two patients.

  • Reproducible Signal Across Patients

    The consistency of PET findings across three patients reinforces evidence of biological activity for intranasal foralumab in dampening neuroinflammation in MSA, a disease with no approved disease-modifying treatments.

  • Next Steps: Further Validation Planned

    Tiziana plans to continue evaluating intranasal foralumab in additional patients to further validate these findings and better characterize the therapy's potential in MSA.


Analysis · TLSA · Life Sciences

The third MSA patient demonstrated up to a 34% reduction in neuroinflammation on PET imaging, closely mirroring the ~35% and 24% reductions observed in the first two patients. Reproducibility across patients strengthens the case that intranasal foralumab has real biological activity in a disease with no approved treatments. While this is early-stage data, consistency is what moves a clinical program from 'interesting signal' to 'potentially real drug.'

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, TLSA was trading at $0.95 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $124.5M. The 52-week trading range was $0.87 to $2.60. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

TLSA - Latest Insights

TLSA
Nov 05, 2026, 2:26 PM EST
Filing Type: 6-K
Importance Score:
7
Price at Filing: $0.6249
Real-time Price: $0.800 info
Change: +$0.1751 (+28%) info
Market Cap: $103.725M info
TLSA
Nov 02, 2026, 7:00 AM EST
Filing Type: 6-K
Importance Score:
9
Price at Filing: $0.890
Real-time Price: $0.800 info
Change: -$0.090 (-10%) info
Market Cap: $103.725M info
TLSA
Nov 02, 2026, 7:00 AM EST
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $0.8685
Real-time Price: $0.800 info
Change: -$0.0685 (-8%) info
Market Cap: $103.725M info
TLSA
Oct 16, 2026, 4:30 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $1.05
Real-time Price: $0.800 info
Change: -$0.250 (-24%) info
Market Cap: $103.725M info
TLSA
Oct 16, 2026, 7:00 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $1.07
Real-time Price: $0.800 info
Change: -$0.270 (-25%) info
Market Cap: $103.725M info